Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Malaria Chemoprevention in Children with Sickle Cell Anemia (EPiTOMISE)
NCT03178643Phase 4Completed
- Sponsor
- Duke University
- Start
- Jan 2018
- Primary completion
- Dec 2020
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of sulfadoxine + pyrimethamine + amodiaquine, dihydroartemisinin + piperaquine in Malaria, sponsored by Duke University. Started Jan 2018; status: completed.
02
Drugs
sulfadoxine + pyrimethamine + amodiaquinedihydroartemisinin + piperaquine
03
Conditions
Malaria
Beyond the preview
Go deeper on NCT03178643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03178643.